Investigating DPP4's Role in Treating Leukemia
Tumor Cell and DNA Detection in the Peripheral Blood of Patients With Hematological Malignancy
This study is testing if a medication that blocks DPP-4 can help prevent relapse in people with acute myeloid leukemia by looking at their blood and bone marrow.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Missouri-Columbia Academic / other |
| Locations | 1 site (Columbia, Missouri) |
| Trial ID | NCT04841447 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect blood and bone marrow specimens from patients with hematological malignancies to understand the effects of Dipeptidyl Peptidase-4 (DPP-4) inhibitors on acute myeloid leukemia (AML) stem cells. The research will explore how DPP-4 contributes to leukemia development and the potential for individualized therapies. By testing DPP-4 inhibitors both in vitro and in vivo, the study seeks to determine if these inhibitors can prevent AML relapse during remission. The findings may provide insights into new treatment strategies for AML and other related blood cancers.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with any form of hematological malignancy.
Not a fit: Patients with impaired decision-making capacities, pregnant women, children, and non-English speakers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective, individualized therapies for patients with leukemia.
How similar studies have performed: While the role of DPP-4 in leukemia has been explored in animal models, this study represents a novel approach using human samples to investigate its implications in hematological malignancies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All hematological malignancy patients. * Must be 18 years old. Exclusion Criteria: * Participants with impaired decision-making capacities; * Pregnant women or fetuses; * Children (under 18 in Missouri, also dependent on State law); * Non-viable neonates or neonates of uncertain viability (neonates=newborns); * Non-English-speaking subjects; * Prisoners.
Where this trial is running
Columbia, Missouri
- University of Missouri — Columbia, Missouri, United States (Recruiting)
Study contacts
- Study coordinator: Xunlei Kang, MD.PhD
- Email: kangxu@health.missouri.edu
- Phone: 5738844524
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.